Skip to main navigation
  • Recent News
  • Investors
  • Contact Us
Avadel pharmaceutical logo
  • Home
  • Our Focus
  • Culture & Careers
  • Recent News
  • Investors
  • Contact Us

Breadcrumb

  1. Home
  2. Investors
  3. Press Releases

Press Releases

Keyword Search

06/29/22

Avadel Pharmaceuticals Provides Corporate Update
Pursuing strategies to accelerate final approval of FT218 NDA Optimizing cost structure to fund stra...
Printer Friendly Version
06/03/22

Avadel Pharmaceuticals and the American Academy of Sleep Medicine Foundation Announce an Exclusive Collaboration on the 2022 Young Investigators Research Forum
DUBLIN, Ireland , June 03, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a bio...
Printer Friendly Version
06/02/22

Avadel Pharmaceuticals to Present at the Jefferies Healthcare Conference
DUBLIN, Ireland , June 02, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a bio...
Printer Friendly Version
05/19/22

Avadel to Present Clinical Data for FT218 at SLEEP 2022
DUBLIN, Ireland , May 19, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biop...
Printer Friendly Version
05/09/22

Avadel Pharmaceuticals Provides Corporate Update and Reports First Quarter 2022 Financial Results
FDA review of NDA for FT218 continues; launch readiness preparations on-track to support potential c...
Printer Friendly Version
05/02/22

Avadel Pharmaceuticals to Provide a Corporate Update and Report First Quarter Financial Results on May 9
DUBLIN, Ireland , May 02, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biop...
Printer Friendly Version
04/26/22

Avadel Pharmaceuticals Provides Comment on Recent Trading Activity
DUBLIN, Ireland , April 26, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a bi...
Printer Friendly Version
04/25/22

Avadel Pharmaceuticals Announces Interim Data from the Open-Label RESTORE Study at the 2022 American Academy of Neurology Annual Meeting
Results from patient preference questionnaire indicate that people with narcolepsy preferred the onc...
Printer Friendly Version
04/06/22

Avadel Pharmaceuticals Announces Publication of Positive Secondary Endpoint Data from Pivotal Phase 3 REST-ON Trial
Once-at-bedtime FT218 demonstrated clinically meaningful improvement in assessments of disrupted nig...
Printer Friendly Version
03/22/22

Avadel Pharmaceuticals to Present at Upcoming Investor Conferences
DUBLIN, Ireland , March 22, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a co...
Printer Friendly Version
03/17/22

Avadel Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results
FDA review of NDA for FT218 is ongoing; commercial and launch preparations on-track to support poten...
Printer Friendly Version
03/14/22

Avadel Pharmaceuticals Announces Appointment of Brandi Robinson as Senior Vice President, Corporate Affairs
DUBLIN, Ireland , March 14, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a co...
Printer Friendly Version
03/14/22

Avadel Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full Year 2021 Financial Results on March 17th
DUBLIN, Ireland , March 14, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a co...
Printer Friendly Version
03/11/22

Avadel Announces New Positive Data for Once-at-Bedtime FT218 for Narcolepsy and Once-Nightly Dosing Preference Among Patients and Clinicians at World Sleep 2022
Discrete choice experiment demonstrated that number of doses was the most important attribute drivin...
Printer Friendly Version
03/10/22

Avadel Pharmaceuticals to Present at the Oppenheimer 32nd Annual Healthcare Conference
DUBLIN, Ireland , March 10, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a co...
Printer Friendly Version
03/01/22

Avadel to Present New Clinical Data at World Sleep 2022
Eight abstracts accepted for poster presentation featuring new data from the Phase 3 REST-ON clinica...
Printer Friendly Version
02/14/22

Avadel Pharmaceuticals Appoints Dr. Douglas Williamson as Chief Medical Officer
DUBLIN, Ireland , Feb. 14, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a com...
Printer Friendly Version
02/10/22

Avadel Pharmaceuticals to Present at the 11th Annual SVB Leerink Global Healthcare Conference
DUBLIN, Ireland , Feb. 10, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a com...
Printer Friendly Version

Tools

  • Print Page
  • RSS
  • E-mail Alerts

Investor Relations

  • Investors
  • News & Events
    • Press Releases
    • Events
    • Presentations
  • Stock Information
    • Stock Quote & Chart
    • Historical Price Lookup
    • Investment Calculator
    • Analyst Coverage
  • Financial Information
    • SEC Filings
    • Financial Reports
    • Quarterly Results
  • Corporate Governance
    • Governance Highlights
    • Management Team
    • Board of Directors
    • Committee Composition
    • Annual General Meeting
  • Shareholder Services
    • Investor FAQs
    • Information Request
    • E-mail Alerts
    • IR Contacts
  • Our Focus
  • Culture & Careers
  • Investors
  • Recent News
  • Contact Us
  • Home
  • Our Focus
  • Culture & Careers
  • Contact Us
  • Recent News
  • Investors
  • Privacy Policy
  • Corporate Compliance
  • Terms and Conditions

The Avadel logo, the droplet brand mark, and other brands are trademarks of an Avadel company. © 2022 Avadel. All rights reserved.

PM-US-AVGEN-0115

We Care About Your Privacy

This website uses cookies. By using our website without changing your cookie settings, you agree to our use of cookies as described in our updated Privacy Policy.

You are about to leave the Avadel website.

Do you want to continue?

Avadel is not responsible for the content or availability of third party sites.